Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)
EPA proposes to ban most uses of trichloroethylene (TCE), a solvent used in some medical device cleaning and spot removers. Med-spas using TCE-containing products must switch to alternatives.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Med-spas using TCE-based cleaning solvents or spot removers for equipment or fabrics. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Proposed rule; final rule expected within 1-2 years. Compliance may be required within 1 year of final rule.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
EPA proposes to prohibit manufacture, processing, and distribution of TCE for all uses except certain laboratory and industrial uses with strict controls.
Who it affects
Med-spas using TCE-based cleaning solvents or spot removers for equipment or fabrics.
What you must do
Identify and replace any TCE-containing products with safer alternatives.
Deadline
Proposed rule; final rule expected within 1-2 years. Compliance may be required within 1 year of final rule.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication